“…Recently, we reported the WID-qEC test, a real-time PCR-based test assessing methylated alleles of regions within the ZSCAN12 and GYPC genes. 9 The WID-qEC test, based on ThinPrep samples, detects 90% to 100% of endometrial cancers independent of collection devices, menopausal status, age, stage, grade, ethnicity and histology and was able to diagnose 91% of endometrial cancers 1 year prior to diagnosis. 9 Here, we have employed a case/control and a hospital-based cohort study to assess whether the WID-qEC test (a) is also able to detect cervical cancer, (b) is also applicable for SurePath samples utilizing the same threshold as defined in our previous studies, (c) is superior to cytology and (d) retains a low false-positive rate when assessed within a hospital-based cohort.…”